Siegfried Holding AG
SIX:SFZN
Net Margin
Siegfried Holding AG
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| CH |
|
Siegfried Holding AG
SIX:SFZN
|
4B CHF |
12%
|
|
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
991.7B USD |
10%
|
|
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
171.7B USD |
15%
|
|
| US |
|
Danaher Corp
NYSE:DHR
|
138B USD |
14%
|
|
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
71.2T KRW |
26%
|
|
| CH |
|
Lonza Group AG
SIX:LONN
|
40B CHF |
10%
|
|
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
268.6B CNY |
27%
|
|
| US |
|
Agilent Technologies Inc
NYSE:A
|
31.9B USD |
18%
|
|
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
30.5B USD |
8%
|
|
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
23.8B USD |
22%
|
|
| FR |
|
Sartorius Stedim Biotech SA
PAR:DIM
|
16.8B EUR |
7%
|
Siegfried Holding AG
Glance View
Nestled in the picturesque landscapes of Zofingen, Switzerland, Siegfried Holding AG operates as a key player in the global pharmaceutical supply chain, crafting a narrative of innovation and precision. With roots tracing back to 1873, this stalwart company has evolved over the decades, now standing as a leading supplier of active pharmaceutical ingredients (APIs) and finished dosage forms to the pharmaceutical industry. Siegfried's operations are defined by a seamless integration of chemistry and technology, embodying Swiss precision in every facet of its production process. The company's trajectory is marked by strategic expansions and acquisitions, allowing it to amass a presence in both Europe and North America, crafting a network that ensures its reliability and reach. At the heart of Siegfried's success lies its business model, a symbiotic partnership with pharmaceutical companies that rely on its vast expertise to bring their products to market. Siegfried essentially straddles both ends of the pharmaceutical value chain, deriving revenue by providing essential APIs as well as a robust offering of finished drugs. The company excels in tailor-made solutions, offering complex manufacturing processes that meet stringent regulatory demands. This dual capability not only diversifies its revenue streams but also buffers it against the volatile dynamics of the pharmaceutical industry. With a focus on quality and customer-centric innovation, Siegfried continues to carve a niche as a trusted collaborator, underpinning the development of health solutions worldwide.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Siegfried Holding AG's most recent financial statements, the company has Net Margin of 12.3%.
You don't have any saved screeners yet